

also used this study to validate the Hungarian translation of the Qmci test in SLE patients.

Results Eighty-seven patients (mean age: 44.97/range: 20–64/), of whom 75 were women (86.2%) and 12 were men (13.8%) were studied. 32 patients (36.8%) had < 12 years of education, 32 patients had grammar school or college educational level (36.8%) and 23 had university degree. Regarding MoCA, the participants' test score was in the range between 17 and 30 points (maximum score in the MoCA test is 30), with mean score of 26.28 (SD = 3.08), which is considered as normal cognition with the 24 cut-off score of the MoCa test. Patients scored a mean of 3.64 point (SD = 1.32) from the maximal 5 points on the delayed recall scale. The Qmci scores were in the range between 49 and 94 points (mean: 80.68/SD = 10.10/), which is classified as normal cognition using the 62 cut-off score (potential maximum for Qmci is 100). Highest deviations from the maximum were observed in the delayed recall domain (13.79, SD = 5.58) and the verbal fluency task (mean 11.78, SD = 2.96 out of the maximal 20 points). With MoCA we detected 16 patients (18.4%) with cognitive impairment, whereas Qmci classified 4 participants (4.6%) with this.

Conclusions Cognitive impairment is present in a considerable proportion of SLE patients under 65 years of age, but the rate is dependent on the tool used. MoCA was a more sensitive test in this cohort, it therefore seems more useful for screening. Although Qmci has a less stringent numerical range to detect mild cognitive impairment, furthermore, it is a quick instrument, it classified less patients with cognitive impairment in our cohort. Analysis of subsets of cognitive function in the tests could help to better delineate the character of cognitive impairment developing in SLE. Further research is required in larger clinical and healthy sample to examine the diagnostic and follow-up value of the tests.

PO.1.15 LUPUS BRAIN FOG: COGNITIVE IMPAIRMENT AND DEPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS

¹S Fasano*, ¹M Patrone, ¹F Riccio, ¹A Milone, ²L Sadile, ²M Fabrizio, ²E Di Caprio, ¹R Tirri, ¹F Ciccia. ¹Rheumatology Unit, University of Campania 'Luigi Vanvitelli' ~ Naples ~ Italy; ²Mental and Physical Health and Preventive Medicine, University of Campania 'Luigi Vanvitelli' ~ Naples ~ Italy

10.1136/lupus-2022-elm2022.48

Purpose To investigate the prevalence and main determinants of cognitive dysfunction, anxiety and depression in a cohort of patients with Systemic Lupus Erythematosus (SLE); to explore the coping strategies and impact of these disorders on quality of life and function.

Methods This observational cross-sectional study recruited patients of the University of Campania 'Luigi Vanvitelli', from February 4th to April 4th, 2022, who were diagnosed with SLE according to the Systemic Lupus International Collaborating Clinics (SLICC) Criteria. Demographic and clinical data, disease activity (SLEDAI-2k), damage (SDI) and concomitant therapies were analyzed. The definitions for remission (DORIS) and 'Lupus Low Disease Activity State' (LLDAS) were applied. At enrollment, each patient underwent a psychiatric evaluation completing the following questionnaires: Hamilton Depression and Anxiety Rating Scales (HAM-D, HAM-A), Montreal Cognitive Assessment (MoCA) and Coping Orientation to Problems Experienced (COPE) Inventory. Health Assessment Questionnaire-Disability Index (HAQ-DI) was also

Abstract PO.1.15 Table 1 Baseline clinical and demographic features of patients enrolled

Sex female n;%	51 (88%)
Age, years mean	45
Disease duration, years mean	16.7
Remission	33 (54%)
LDA	43 (76%)
SLICC damage index median (range)	1 (0-6)
HCQ	48 (78%)
Azathioprine	12 (19%)
Mycophenolatemofetil	11 (18%)
Methotrexate	1 (1%)
Belimumab	1 (6%)
Glucocorticoids	33 (54%)

performed. The Spearman test was used for linear correlation. Multivariate analysis was performed by multiple linear and logistic regression.

Results 61 consecutive patients with SLE were enrolled, the majority female (88%) and Caucasian with a mean age of 46 years. 70% were in remission or in LDA. The prevalence of cognitive dysfunction was 65%, executive function and memory were the most affected domains. We found isolated anxiety in 3% and isolated depression in 50.7% of patients, even if mild. Regarding coping strategies, SLE patients reported higher scores on emotion-focused coping, with respect to the other two coping strategies ($p < 0,001$). Pearson's correlation analysis highlighted a relationship between higher levels of cognitive impairment and worse quality of life ($r = -0.38$, $p = 0.002$) and between hypocomplementemia and depression ($r = -0,25$; $P = 0,04$). AntidsDNA antibody positivity was slightly significant ($r = 0,22$; $P = 0,08$). Our analysis also highlighted a positive correlation between emotion-focused and avoidance-focused strategies (0.43 ; $P = 0.0005$). In the multivariate analysis, higher scores on the HAM-D questionnaire (higher levels of depression) were found to be independently associated with higher HAQ score (OR:1.2; $p = 0.03$). Moreover, patients with active disease tend to be more depressed compared to patients in LDA or in remission ($p : 0.04$).

Fibromyalgia was independently associated with depression (OR: 3.85 $p : 0.03$). Depression was found to be significantly linked to patients' worse quality of life, irrespective of disease activity (OR:1.19; $p = 0.01$). Depression, anxiety and fibromyalgia were not associated with objective cognitive dysfunction.

Conclusion Our study confirms the high prevalence of cognitive dysfunction and depressive symptoms in SLE patients and determine a strong negative impact on function and quality of life.

In the context of a multidisciplinary management, collaboration with clinical psychologists should be considered, to improve both coping strategies, patients' perception of health status and quality of life.

PO.1.16 LIMBIC ENCEPHALITIS: A RARE COMPLICATION OF SYSTEMIC LUPUS ERYTHEMATOSUS

T Asmaa*, A Wafa, W Chawad, F Ibourci El Idrissi, H Harmouche, M Maamar, H Khibri, Z Tazi Mezalek, M Adnaoui. Department of internal medicine, Ibn Sina's Hospital ~ Rabat ~ Morocco

10.1136/lupus-2022-elm2022.49

Purpose Neurological manifestations during systemic lupus (SLE) are common, and can jeopardize the functional or vital prognosis of patients .